Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 5/2022

19.08.2022 | Behavioral-Bio-Medical Interface (RJ DiClemente and JL Brown, Section Editors)

HIV Prevention Tools Across the Pregnancy Continuum: What Works, What Does Not, and What Can We Do Differently?

verfasst von: Melissa Latigo Mugambi, Jillian Pintye, Renee Heffron, Ruanne Vanessa Barnabas, Grace John-Stewart

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Multiple tools exist to support the primary prevention of HIV in pregnant and postpartum women; however, there are opportunities to enhance their use and impact. This review summarizes the current status of HIV prevention tools and existing gaps and opportunities to improve their use along the pregnancy care continuum.

Recent Findings

HIV screening efforts have steadily improved with close to universal screening of pregnant women in several East and Southern African countries. Strategies to implement partner testing through the distribution of HIV self-test kits are promising though linkage to care remains challenging. Syphilis screening rates are increasing though detection of other sexually transmitted infections could benefit from improved diagnostic capacity. Male and female condoms are rarely used and are often not the optimal tool of choice during pregnancy. Oral pre-exposure prophylaxis (PrEP) is a promising tool, although barriers such as the need for daily adherence, side effects, and stigma may limit its use. There is a growing pipeline of PrEP agents with alternative delivery platforms that might suit women’s preferences better and supports the notion that choice is vital to improving HIV prevention coverage during the pregnancy-postpartum continuum.

Summary

Clear guidance on which tools to use and how to use them, safety data supporting their use, and surveillance data documenting the scale and effectiveness of the tools will be imperative in establishing a path to more impactful prevention efforts among pregnant and postpartum women.
Literatur
1.
UNAIDS D. UNAIDS 2020 Global Report, UNAIDS Joint United Nations Programme on HIV. Geneva: AIDS; 2020.
2.
Rosenberg NE, et al. Empirical estimates of adult HIV incidence across 12 countries in sub-Saharan Africa. in CROI. 2022.
3.
Dinh T-H, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS One. 2015;10(5):e0125525–e0125525.PubMedPubMedCentralCrossRef
4.
Tessema ZT, et al. Determinants of accessing healthcare in Sub-Saharan Africa: a mixed-effect analysis of recent demographic and health surveys from 36 countries. BMJ Open. 2022;12(1):e054397–e054397.PubMedPubMedCentralCrossRef
5.
WHO, Preventing HIV during pregnancy and breastfeeding in the context of PrEP. 2017, World Health Organization: Geneva, Switzerland.
6.
Worku MG, Teshale AB, Tesema GA. Prevalence and associated factors of HIV testing among pregnant women: a multilevel analysis using the recent demographic and health survey data from 11 East African countries. HIV/AIDS (Auckland, N.Z.) 2021;13:181–189.
7.
Awopegba OE, et al. Prenatal care coverage and correlates of HIV testing in sub-Saharan Africa: insight from demographic and health surveys of 16 countries. PLoS One. 2020;15(11): e0242001.PubMedPubMedCentralCrossRef
8.
Bolu OO, et al. Approaches for scaling up human immunodeficiency virus testing and counseling in prevention of mother-to-child human immunodeficiency virus transmission settings in resource-limited countries. Am J Obstet Gynecol. 2007;197(3):S83–9.PubMedCrossRef
9.
Ndege S, et al. HIV prevalence and antenatal care attendance among pregnant women in a large home-based HIV counseling and testing program in Western Kenya. PLoS One. 2016;11(1): e0144618.PubMedPubMedCentralCrossRef
10.
Nakanwagi M, et al. Low proportion of women who came knowing their HIV status at first antenatal care visit, Uganda, 2012–2016: a descriptive analysis of surveillance data. BMC Pregnancy Childbirth. 2020;20(1):498.PubMedPubMedCentralCrossRef
11.
Joseph Davey D, et al. Sexual risk during pregnancy and postpartum periods among HIV-infected and -uninfected South African women: implications for primary and secondary HIV prevention interventions. PLoS One. 2018;13(3):e0192982–e0192982.PubMedPubMedCentralCrossRef
12.
Thomson K, et al. Increased risk of female HIV-1 acquisition throughout pregnancy and postpartum: a prospective per-coital act analysis among women with HIV-1 infected partners. J Infect Dis. 2018.
13.
Moller A-B, et al. Early antenatal care visit: a systematic analysis of regional and global levels and trends of coverage from 1990 to 2013. Lancet Glob Health. 2017;5(10):e977–83.PubMedPubMedCentralCrossRef
14.
Munthali M, et al. Knowledge and perceptions of preconception care among health workers and women of reproductive age in Mzuzu City, Malawi: a cross-sectional study. Reprod Health. 2021;18(1):229.PubMedPubMedCentralCrossRef
15.
Teshome F, et al. What do women know before getting pregnant? Knowledge of preconception care and associated factors among pregnant women in Mana district, Southwest Ethiopia: a community-based cross-sectional study. BMJ Open. 2020;10(7): e035937.PubMedPubMedCentralCrossRef
16.
Dean SV, et al. Born too soon: care before and between pregnancy to prevent preterm births: from evidence to action. Reprod Health. 2013;10(1):1–16.
17.
Mugambi ML, et al. Design and evaluation of strategies to implement HIV prevention interventions for pregnant women in community pharmacy settings in western Kenya: a mixed-methods study protocol. BMJ Open. 2021;11(12): e052311.PubMedPubMedCentralCrossRef
18.
Pintye J, et al. A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis. 2017;64(6):751–8.PubMed
19.
Balkus JE, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. (1999), 2016;72(3):333.
20.
Kahle EM, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. (1999), 2013;62(3):339.
21.
Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. The Lancet. 2008;372(9639):669–84.CrossRef
22.
Organization, W.H. Prevention of mother-to-child transmission (PMTCT). Briefing Note. Geneva: Department of HIV/AIDS, 2007.
23.
World Health Organization, Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. 2012.
24.
Orne-Gliemann J, et al. Couple-oriented prenatal HIV counseling for HIV primary prevention: an acceptability study. BMC Public Health. 2010;10(1):197.PubMedPubMedCentralCrossRef
25.
Clark J, et al. Improving male involvement in antenatal care in low and middle-income countries to prevent mother to child transmission of HIV: A realist review. PLoS One. 2020;15(10):e0240087–e0240087.PubMedPubMedCentralCrossRef
26.
Cornell M, et al. HIV services in sub-Saharan Africa: the greatest gap is men. The Lancet. 2021;397(10290):2130–2.CrossRef
27.
Giguère K, et al. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data. The Lancet HIV. 2021;8(5):e284–93.PubMedPubMedCentralCrossRef
28.
Mohlala BK, Boily MC, Gregson S. The forgotten half of the equation: randomized controlled trial of a male invitation to attend couple voluntary counselling and testing. AIDS. 2011;25(12):1535–41.PubMedCrossRef
29.
30.•
Choko AT, et al. Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial. Lancet Global Health. 2021;9(7):e977–e988. This three-arm cluster randomized trial in Malawi found an increase in HIV testing rates among male partners who received HIV self-tests from pregnant women attending antenatal care.
31.
Masters SH, et al. Promoting partner testing and couples testing through secondary distribution of HIV self-tests: a randomized clinical trial. PLoS Med. 2016;13(11): e1002166.PubMedPubMedCentralCrossRef
32.
Choko AT, et al. Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial. Lancet Glob Health. 2021;9(7):e977–88.PubMedPubMedCentralCrossRef
33.
Hershow RB, et al. Perspectives on HIV partner notification, partner HIV self-testing and partner home-based HIV testing by pregnant and postpartum women in antenatal settings: a qualitative analysis in Malawi and Zambia. J Int AIDS Soc. 2019;22: e25293.PubMedPubMedCentralCrossRef
34.
Korte JE, et al. HIV testing preferences among pregnant women attending antenatal care and their male partners: a discrete choice experiment in Uganda. Afr J AIDS Res. 2019;18(4):332–40.PubMedPubMedCentralCrossRef
35.
Ngumbau NM. HIVST acceptance and PrEP initiation among pregnant women at high risk of HIV in Homa Bay and Siaya counties, Kenya. 2021.
36.
Jamil MS, et al. Examining the effects of HIV self-testing compared to standard HIV testing services in the general population: a systematic review and meta-analysis. EClinicalMedicine. 2021;38: 100991.PubMedPubMedCentralCrossRef
37.
Sibanda EL, Mavhu W. Secondary HIV self-test distribution increases male partner testing. Lancet Glob Health. 2021;9(12):e1632–3.PubMedCrossRef
38.
Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sexually transmitted infections. 1999;75(1):3–17.PubMedPubMedCentralCrossRef
39.
World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission (EMTCT) of HIV and syphilis. WHO, Editor. Geneva, Switzerland; 2014.
40.
Swartzendruber A, et al. Introduction of rapid syphilis testing in antenatal care: a systematic review of the impact on HIV and syphilis testing uptake and coverage. Int J Gynaecol Obstet. 2015;130(Suppl 1):S15-21.PubMedPubMedCentralCrossRef
41.
Korenromp EL, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes—estimates for 2016 and progress since 2012. PLoS One. 2019;14(2): e0211720.PubMedPubMedCentralCrossRef
42.
Low N, et al. Global control of sexually transmitted infections. Lancet. 2006;368(9551):2001–16.PubMedCrossRef
43.
Joseph Davey DL, et al. Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015: a systematic review. Sex Transm Dis. 2016;43(7):450–8.PubMedCrossRef
44.
45.
World Health Organization. Guidelines for the management of sexually transmitted infections. Revised 2003. WHO Library Cataloguing-in-Publication Data. Geneva, Switzerland.
46.
Mlisana K, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis. 2012;206(1):6–14.PubMedPubMedCentralCrossRef
47.
Bosu WK. Syndromic management of sexually transmitted diseases: is it rational or scientific? Trop Med Int Health. 1999;4(2):114–9.PubMedCrossRef
48.
Vuylsteke B. Current status of syndromic management of sexually transmitted infections in developing countries. Sex Transm Infect. 2004;80(5):333–4.PubMedPubMedCentralCrossRef
49.
White RG, et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect. 2008;84(7):528–34.PubMedCrossRef
50.
Hawkes S, et al. Reproductive-tract infections in women in low-income, low-prevalence situations: assessment of syndromic management in Matlab, Bangladesh. Lancet. 1999;354(9192):1776–81.PubMedCrossRef
51.
Morikawa E, et al. Acceptability and feasibility of integrating point-of-care diagnostic testing of sexually transmitted infections into a South African antenatal care program for HIV-infected pregnant women. Infect Dis Obstet Gynecol. 2018;2018:3946862.PubMedPubMedCentralCrossRef
52.
Wynn A, et al. Acceptability and feasibility of sexually transmitted infection testing and treatment among pregnant women in Gaborone, Botswana, 2015. Biomed Res Int. 2016;2016:1251238.PubMedPubMedCentralCrossRef
53.
Wynn A, et al. Bridging the gap between pilot and scale-up: a model of antenatal testing for curable sexually transmitted infections from Botswana. Sex Transm Dis. 2022;49(1):59–66.PubMedCrossRef
54.
Unger JA, et al. Patient-delivered partner treatment for chlamydia, gonorrhea, and trichomonas infection among pregnant and postpartum women in Kenya. Sex Transm Dis. 2015;42(11):637.PubMedPubMedCentralCrossRef
55.
Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database System Rev. 2002(1).
56.
Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454–61.PubMedPubMedCentral
57.
58.
Kinuthia J, et al. HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS. 2015;29(15):2025–33.PubMedCrossRef
59.
Maharajh R, Haffejee F. Exploring male condom use among women in South Africa: a review of the literature. Afr J AIDS Res. 2021;20(1):6–14.PubMedCrossRef
60.
Chapola JC, et al. Women’s perspectives on relationship dynamics with their partners and their role in HIV acquisition, HIV disclosure, hormonal contraceptive uptake, and condom use. Afr J AIDS Res. 2021;20(1):61–9.PubMedPubMedCentralCrossRef
61.
Joseph Davey D, et al. Risk perception and sex behaviour in pregnancy and breastfeeding in high HIV prevalence settings: programmatic implications for PrEP delivery. PLoS One. 2018;13(5): e0197143.PubMedPubMedCentralCrossRef
62.
Moore L, et al. Knowledge, attitudes, practices and behaviors associated with female condoms in developing countries: a scoping review. Open Access J Contracept. 2015;6:125–42.PubMedPubMedCentralCrossRef
63.
Peters A, Jansen W, van Driel F. The female condom: the international denial of a strong potential. Reprod Health Matters. 2010;18(35):119–28.PubMedCrossRef
64.
Wiyeh AB, et al. Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis. BMC Public Health. 2020;20(1):319.PubMedPubMedCentralCrossRef
65.
Haffejee F, Maharajh R. Addressing female condom use among women in South Africa: a review of the literature. Int J Sex Health. 2019;31(3):297–307.CrossRef
66.
Lopez LM, et al. Behavioral interventions for improving condom use for dual protection. Cochrane Database System Rev. 2013(10).
67.
Moreno R, et al. Structural and community-level interventions for increasing condom use to prevent the transmission of HIV and other sexually transmitted infections. Cochrane Database System Rev. 2014(7).
68.
Young Holt B, Turpin JA, Romano J. Multipurpose prevention technologies: opportunities and challenges to ensure advancement of the most promising MPTs. Front Reprod Health. 2021;3.
69.
Abdool Karim S, et al. The need for multipurpose prevention technologies in sub-Saharan Africa. BJOG: Int J Obstetr Gynaecol. 2014;121:27–34.
70.
Vickerman P, et al. HIV prevention is not all about HIV – using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20(1):704.PubMedPubMedCentralCrossRef
71.
Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England). 2016;30(12):1973.CrossRef
72.
73.
Mayer KH, Krakower D. Administration of pre-exposure prophylaxis against HIV infection. UpToDate. Published July, 2019. 16.
74.
Joseph Davey DL, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23(1):e25426–e25426.PubMedPubMedCentralCrossRef
75.
Stalter RM, Pintye J, Mugwanya KK. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. Expert Opin Drug Saf. 2021;20(11):1367–73.PubMedPubMedCentralCrossRef
76.•
Kinuthia J, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–e48. This implementation study of PrEP in maternal and child health clinics in Kenya, found that pregnant and postpartum women who had a partner living with an HIV were more likely to initiate and continue PrEP.
77.•
Joseph Davey DL, et al. Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa. J Int AIDS Soc. 2022;25(2):e25866. This cohort study in South Africa, found high rates or PrEP initiation and continuation among pregnant and postpartum women.
78.
Pintye J, et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. JAIDS J Acquir Immune Defic Syndr. 2021;86(4):e83–9.PubMedCrossRef
79.
Davies N, Heffron R. Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sexual health. 2018;15(6):501–12.PubMedPubMedCentralCrossRef
80.
Pintye J, et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. Lancet HIV. 2020;7(8):e582–92.PubMedPubMedCentralCrossRef
81.
Davey DLJ, et al. Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. Lancet HIV. 2022.
82.
Moretlwe SD, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. J Int AIDS Soc. 2021;24(S1):8–9.
83.
Thoueille P, et al. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290–302.PubMedCrossRef
84.
Organization W.H. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. WHO News. 2021.
85.
Schürmann D, et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV. 2020;7(3):e164–72.PubMedCrossRef
86.
Pintye J, et al. Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal and child health and family planning clinics. AIDS (London, England). 2019;33(8):1369–78.CrossRef
87.
Jarolimova J, et al. Curable sexually transmitted infections among women with HIV in sub-Saharan Africa: systematic review and meta-analysis. AIDS (London, England). 2022.
88.
Mashaphu S, et al. Condom use consistency among South African HIV serodiscordant couples following an HIV risk-reduction intervention. Int J STD AIDS. 2022;09564624221076617.
89.
Shallie PD, Haffejee F. Systematic review and meta-analysis assessing the knowledge and use of the female condom among Nigerians. Afr Health Sci. 2021;21(3):1362–74.PubMedPubMedCentralCrossRef
Metadaten
Titel
HIV Prevention Tools Across the Pregnancy Continuum: What Works, What Does Not, and What Can We Do Differently?
verfasst von
Melissa Latigo Mugambi
Jillian Pintye
Renee Heffron
Ruanne Vanessa Barnabas
Grace John-Stewart
Publikationsdatum
19.08.2022
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 5/2022
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-022-00621-1

Weitere Artikel der Ausgabe 5/2022

Current HIV/AIDS Reports 5/2022 Zur Ausgabe

Behavioral-Bio-Medical Interface (RJ DiClemente and JL Brown, Section Editors)

Measuring and Addressing Stigma Within HIV Interventions for People Who Use Drugs: a Scoping Review of Recent Research

Complications of HIV and Antiretroviral Therapy (GA McComsey, Section Editor)

COVID-19 Outcomes and Risk Factors Among People Living with HIV

eHealth and HIV (J Stekler and D Katz, Section Editors)

HIV Care Meets Telehealth: a Review of Successes, Disparities, and Unresolved Challenges

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Using Behavioral Economics to Support PrEP Adherence for HIV Prevention

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Examining the Use of HIV Self-Testing to Support PrEP Delivery: a Systematic Literature Review

Global Health (S Vermund, Section Editor)

Overcoming Vaccine Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise